Ars Pharmaceuticals Inc (SPRY)

LiquidTheta® LEAPS LIVE Actionable Alert Asset: $SPRY Current Share Price: $10.31 Contracts: $SPRY April 17, 2026 $12 Calls Scale in: $1.58- $1.94 Scale out: $2.46-$3.17 Can Easily Capture: 60% ROI Blended DTE: 196 Days | Join Elites here: https://liquidtheta.com/options

$SPRY $AQST I'm making cash on both these stocks and will continue to do so. Only neophytes or combative children think it has to be one or the other. I really don't care who takes a larger market share - plenty of market for both to prosper, especially given where they're at in their commercialization cycles. I own competing bank stocks, cybersecurity stocks, big pharma stocks, retail stocks, oil stocks - why not also own competing non-injectable epinephrine stocks. It's called portfolio diversification.

@StocktwitsEarnings Check out $SPRY Bout to run and never look back…just like $PLTR when I bought at $15…sold that too soon. Not making same decision on $SPRY Neffy is the world’s first needle-free epinephrine spray, already approved and just launched in the U.S., EU (including Germany), UK, and Japan, with filings in Canada, Australia, New Zealand, and China. It tackles a massive unmet need, expands to hives and other allergic conditions, and offers a once-in-a-generation growth story with multi-fold upside. Launched by people that helped launch Narcan. Key difference is they have patent protection till 2039 and additional worldwide approvals incoming.

@TheProphetOfProfit Check out $SPRY Bout to run and never look back…just like $PLTR when I bought at $15…sold that too soon. Not making same decision on $SPRY Neffy is the world’s first needle-free epinephrine spray, already approved and just launched in the U.S., EU (including Germany), UK, and Japan, with filings in Canada, Australia, New Zealand, and China. It tackles a massive unmet need, expands to hives and other allergic conditions, and offers a once-in-a-generation growth story with multi-fold upside. Launched by people that helped launch Narcan. Key difference is they have patent protection till 2039 and additional worldwide approvals incoming.

$PLTR $SPRY I stay away from medical stuff, lost money evrry time. Good luck to you if you understand it

@alphatrends Check out $SPRY Bout to run and never look back…just like $PLTR when I bought at $15…sold that too soon. Not making same decision on $SPRY Neffy is the world’s first needle-free epinephrine spray, already approved and just launched in the U.S., EU (including Germany), UK, and Japan, with filings in Canada, Australia, New Zealand, and China. It tackles a massive unmet need, expands to hives and other allergic conditions, and offers a once-in-a-generation growth story with multi-fold upside. Launched by people that helped launch Narcan. Key difference is they have patent protection till 2039 and additional worldwide approvals incoming.

@wha1e Check out $SPRY Bout to run and never look back…just like $PLTR when I bought at $15…sold that too soon. Not making same decision on $SPRY Neffy is the world’s first needle-free epinephrine spray, already approved and just launched in the U.S., EU (including Germany), UK, and Japan, with filings in Canada, Australia, New Zealand, and China. It tackles a massive unmet need, expands to hives and other allergic conditions, and offers a once-in-a-generation growth story with multi-fold upside. Launched by people that helped launch Narcan. Key difference is they have patent protection till 2039 and additional worldwide approvals incoming.

@eWhispers Check out $SPRY Bout to run and never look back…just like $PLTR when I bought at $15…sold that too soon. Not making same decision on $SPRY Neffy is the world’s first needle-free epinephrine spray, already approved and just launched in the U.S., EU (including Germany), UK, and Japan, with filings in Canada, Australia, New Zealand, and China. It tackles a massive unmet need, expands to hives and other allergic conditions, and offers a once-in-a-generation growth story with multi-fold upside. Launched by people that helped launch Narcan. Key difference is they have patent protection till 2039 and additional worldwide approvals incoming.

$SPRY Multi stage short squeeze incoming…. Best of luck to all of us trying to create generational wealth. Normally, when a biotech raises cash, the rumors/leaks of a dilutive secondary swirl around for weeks — shorts get ready, pile in, and push the stock lower into the offering. But with SPRY: Why the $250M Facility Blindsided Shorts Non-dilutive structure: Shorts were 100% leaning on “they’ll dilute.” Instead, SPRY secured a credit facility through 2030 that added runway but didn’t touch the float. Secrecy: This wasn’t a marketed equity raise; it was a quiet, strategic negotiation with RA Capital & OMERS. Shorts had zero time to prepare. Why Shorts Are “Shitting Their Pants” Now Their core thesis is dead. Borrow availability is tight (~hundreds of thousands, not millions). 29% of float short means if even 25–50% try to cover, it rips into ATHs. Big money is long: RA + OMERS aren’t traders; they’re anchors. Shorts are effectively shorting against these guys. ⚡ The Trap They’re In 1. If they cover now, they crystallize losses but escape before the crowd. 2. If they hold, they gamble that the stock dips again — but every new catalyst (Canada/NZ approvals, earnings) risks triggering a chain reaction of covering. It’s why dips are now being soaked up instantly — early shorts are slipping out, but the stubborn ones are cornered. 👉 In plain English: The $250M non-dilutive deal was a stealth nuke. Shorts didn’t see it coming, and now they’re stuck in a burning theater with fewer and fewer exits.